Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Columns & Departments

IP News Image

IP News

Jeff Ginsberg & Collin Hong

Federal Circuit: ITC Did Not Err In Finding Violation of Section 337 Federal Circuit: PTAB Did Not Err In Claim Construction and Finding Certain Claims Obvious

Features

Protecting Technology-Assisted Works and Inventions: Where Does Smart Technology End and AI Begin? Image

Protecting Technology-Assisted Works and Inventions: Where Does Smart Technology End and AI Begin?

Ed Lanquist, Jr. & Dominic Rota

At what point does a "smart" computing system, or advanced software program, qualify as AI in the eyes of pertinent regulatory or judicial authorities? When is an individual considered to have merely deployed an AI-based computing tool to assist with creating a work of art or conceiving of a technological innovation? Each of these questions is explored in this article, giving consideration to currently prevailing guidelines from administrative bodies and the courts.

Features

All the News That's Fit to Pinch Image

All the News That's Fit to Pinch

Jonathan Moskin & Rachel Pauley

The emerging cases by authors and copyright owners challenging various generative AI programs for using copyrighted materials are certain to create new troubles for the courts being asked to apply the fair use doctrine to this important new technology.

Features

Recent Patent Trial and Appeal Board Approaches to Patent Claims on Medical Technology Implementing AI Image

Recent Patent Trial and Appeal Board Approaches to Patent Claims on Medical Technology Implementing AI

Jim Soong

Each decision involves reversal of a prior art rejection and contrasts with the other decisions on subject matter eligibility, revealing different PTAB approaches and results that can inform prosecution and appeal strategies.

Features

Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi' Image

Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'

Leanne Rakers & Caley McCarthy

The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's May 2023 ruling in Amgen Inc. v. Sanofi, a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.

Features

Can Artificial Intelligence Patents Overcome §112 Requirements?, Part 2 Image

Can Artificial Intelligence Patents Overcome §112 Requirements?, Part 2

Mark Liang, Paige Hardy & Grace McFee

Part Two of a Two-Part article While the last decade has seen a dramatic increase in the number of AI patents, such patents face difficulty in overcoming the patent-eligibility challenges under §101 and Alice. Section 101, however, is not the only hurdles AI patents must overcome. Section 112, with its written description, enablement, and definiteness requirements, presents additional obstacles.

Features

How Patent Owners Can Leverage Climate Change Programs In Their IP Strategies Image

How Patent Owners Can Leverage Climate Change Programs In Their IP Strategies

Gregory D. Len & Rachel Sullivan

The USPTO has created or expanded several programs to promote the development of sustainable energy. For patent owners and inventors in the energy sector, these programs can provide a financial and administrative edge for the development and protection of their intellectual property, as well as play a beneficial role their overall IP strategy.

Columns & Departments

IP News Image

IP News

Howard Shire & Justin Tilghman

In Patrick v. Poree, the United States Court of Appeals for the Eleventh Circuit affirmed the denial of default judgment and summary judgment of copyright infringement claims based on a lack of evidence that the plaintiff owned a valid copyright.

Features

A Scoreboard of Notable Cases In AI and Copyright Image

A Scoreboard of Notable Cases In AI and Copyright

Stan Soocher

Artificial intelligence has dominated intellectual property news since the public introduction of OpenAI's ChatGPT, the generative AI chatbot, in November 2022. Now, 2024 starts off with court decisions and procedural rulings having taken shape in 2023 lawsuits that were filed over the collision of creative content with generative AI programs.

Features

Can Artificial Intelligence Patents Survive Alice? Image

Can Artificial Intelligence Patents Survive Alice?

Mark Liang. Paige Hardy & Grace McFee

Part One of a Two-Part Article Under the current Alice framework, those attempting to patent AI innovations face an uphill battle. But, as the caselaw demonstrates, inventors and patent drafters can take steps to reduce the risk of AI patent claims being invalidated as abstract ideas.

Need Help?

  1. Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
  2. Need other assistance? email Customer Service or call 1-877-256-2472.

MOST POPULAR STORIES

  • Private Equity Valuation: A Significant Decision
    Insiders (and others) in the private equity business are accustomed to seeing a good deal of discussion ' academic and trade ' on the question of the appropriate methods of valuing private equity positions and securities which are otherwise illiquid. An interesting recent decision in the Southern District has been brought to our attention. The case is <i>In Re Allied Capital Corp.</i>, CCH Fed. SEC L. Rep. 92411 (US DC, S.D.N.Y., Apr. 25, 2003). Judge Lynch's decision is well written, the Judge reviewing a motion to dismiss by a business development company, Allied Capital, against a strike suit claiming that Allied's method of valuing its portfolio failed adequately to account for i) conditions at the companies themselves and ii) market conditions. The complaint appears to be, as is often the case, slap dash, content to point out that Allied revalued some of its positions, marking them down for a variety of reasons, and the stock price went down - all this, in the view of plaintiff's counsel, amounting to violations of Rule 10b-5.
    Read More ›